Trial · NCT01411774
D-cycloserine Augmentation of Cognitive Behavioral Therapy (CBT) for Pediatric Obsessive-compulsive Disorder (OCD)
NCT01411774, Phase 3, Completed, University of South Florida; results first posted 2018-01-23
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. D-cycloserine Augmentation of Cognitive Behavioral Therapy (CBT) for Pediatric Obsessive-compulsive Disorder (OCD). Trials, record NCT01411774. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01411774
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- D-cycloserine Augmentation of Cognitive Behavioral Therapy (CBT) for Pediatric Obsessive-compulsive Disorder (OCD)
- NCT number
- NCT01411774
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 142 participants, actual
- Lead sponsor
- University of South Florida
- Conditions
- Obsessive-compulsive Disorder
- Interventions
- Cognitive-behavioral therapy, d-cycloserine, Pill placebo
- First posted
- 2011-08-08
- Last updated
- 2018-01-23
- Results first posted
- 2018-01-23
- Limitations and caveats
We did not measure distress ratings within each exposure session, which prohibits examining whether D-cycloserine enhances outcomes when within-session distress reduction is achieved.~The sample was primarily of white race/ethnicity.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Children's Yale-Brown Obsessive-Compulsive Scale. | 10 weeks | The Children's Yale-Brown Obsessive-Compulsive Scale measures the severity of OCD symptoms. There are 10 questions that are summed to arrive at a total score, with higher scores representing more severe OCD symptoms (scores range from 0-40). |
| Secondary | Clinical Global Impression-Severity | 10 weeks | The Clinical Global Impression-Severity involves a trained clinician rating how severe the person's OCD symptoms are on a 0 to 6 scale, with higher scores corresponding to more severe symptoms. This rating only involves a clinician completing a single item. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Children's Yale-Brown Obsessive-Compulsive Scale. | 10 weeks | units on a scale | MEAN | |
| SECONDARY | Clinical Global Impression-Severity | 10 weeks | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Children's Yale-Brown Obsessive-Compulsive Scale. | Cognitive-behavioral Therapy Plus Pill Placebo | 13.53 | 95% Confidence Interval 11.22 to 15.85 | units on a scale | |
| Children's Yale-Brown Obsessive-Compulsive Scale. | Cognitive-behavioral Therapy Plus D-cycloserine | 13.98 | 95% Confidence Interval 11.6 to 16.36 | units on a scale | |
| Clinical Global Impression-Severity | Cognitive-behavioral Therapy Plus Pill Placebo | 2.23 | 95% Confidence Interval 1.89 to 2.56 | units on a scale | |
| Clinical Global Impression-Severity | Cognitive-behavioral Therapy Plus D-cycloserine | 2.28 | 95% Confidence Interval 1.94 to 2.63 | units on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cognitive-behavioral Therapy Plus Pill Placebo | 72 | |
| Overall Study | STARTED | Cognitive-behavioral Therapy Plus D-cycloserine | 70 | |
| Overall Study | COMPLETED | Cognitive-behavioral Therapy Plus Pill Placebo | 72 | |
| Overall Study | COMPLETED | Cognitive-behavioral Therapy Plus D-cycloserine | 67 | |
| Overall Study | NOT COMPLETED | Cognitive-behavioral Therapy Plus Pill Placebo | 0 | |
| Overall Study | NOT COMPLETED | Cognitive-behavioral Therapy Plus D-cycloserine | 3 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Cognitive-behavioral Therapy Plus Pill Placebo | 0 | 72 |
| Total, all-cause mortality | Cognitive-behavioral Therapy Plus D-cycloserine | 0 | 70 |
| Total, other adverse events | Cognitive-behavioral Therapy Plus Pill Placebo | 0 | 72 |
| Total, other adverse events | Cognitive-behavioral Therapy Plus D-cycloserine | 0 | 70 |
| Total, serious adverse events | Cognitive-behavioral Therapy Plus Pill Placebo | 0 | 72 |
| Total, serious adverse events | Cognitive-behavioral Therapy Plus D-cycloserine | 0 | 70 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 20817153 | BACKGROUND |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01MH093381 | 1/2-D-Cycloserine Augmentation of CBT for Pediatric OCD | STORCH, ERIC A. | UNIVERSITY OF SOUTH FLORIDA | NATIONAL INSTITUTE OF MENTAL HEALTH | 2011 to 2014 |
Source NIH RePORTER
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Cognitive-behavioral Therapy Plus Pill Placebo vs Cognitive-behavioral Therapy Plus D-cycloserine: deaths from any cause | Trial comparisons |
| Cognitive-behavioral Therapy Plus Pill Placebo vs Cognitive-behavioral Therapy Plus D-cycloserine: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01411774
GET https://conductscience.org/api/trials/v1/NCT01411774/registered